BridgeBio Oncology Therapeutics, Inc BBOT
3.95
(0.04)
(1.00%)
as of 25 Sep
- Market cap
- $319.9M
- P/E
- 0.0×
Follow BBOT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+4 more quarters Free account |
13.33 | 12.34 | 6.16 | 4.69 |
Net Debt/EBITDA |
9.56 | 9.85 | 5.49 | 3.76 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 1.09 | 0.85 | 0.79 | |
Capex/Depreciation |
(0.77) | (0.38) | (0.13) | (0.25) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.66) | (1.36) | (0.45) | (0.55) | |
Cash per Share |
10.77 | 13.66 | 3.15 | 2.82 | |
Shareholders Equity per Share |
10.27 | 13.20 | 4.65 | 4.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.27 | 13.20 | 4.65 | 4.04 | |
Free Cash Flow |
(28.91) | (42.31) | (35.94) | (44.41) | |
Working Capital |
440.30 | 397.36 | 223.24 | 190.74 | |
Capital Expenditures |
(0.14) | (0.07) | (0.02) | (0.05) | |
Net Current Asset Value |
437.92 | 395.11 | 221.14 | 188.78 | |
| Other line items | |||||
Quick Ratio |
13.12 | 12.15 | 5.84 | 4.38 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.66) | (1.36) | (0.45) | (0.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | — | 0.37 | |
Average Payables |
— | — | — | 4.90 | |
Average Assets |
242.40 | 224.19 | 208.82 | 188.35 | |
Average Common Equity |
— | — | — | 72.24 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates